DS 7250

Drug Profile

DS 7250

Alternative Names: DS-7250

Latest Information Update: 07 Aug 2013

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Diacylglycerol O acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 31 Jul 2013 Discontinued - Phase-I for Diabetes mellitus in European Union (PO)
  • 31 Jul 2013 Discontinued - Phase-I for Diabetes mellitus in USA (PO)
  • 31 Jul 2013 Discontinued - Phase-I for Obesity in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top